Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,102 shares of the medical equipment provider’s stock after selling 1,548 shares during the quarter. Retirement Systems of Alabama’s holdings in Zimmer Biomet were worth $4,553,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Dunhill Financial LLC increased its holdings in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC purchased a new position in Zimmer Biomet in the 3rd quarter valued at $28,000. Brooklyn Investment Group purchased a new position in Zimmer Biomet in the 3rd quarter valued at $35,000. R Squared Ltd purchased a new position in Zimmer Biomet in the 4th quarter valued at $63,000. Finally, Mather Group LLC. grew its position in Zimmer Biomet by 100.9% in the 4th quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock valued at $70,000 after buying an additional 332 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Trading Down 0.5 %

Shares of ZBH stock opened at $100.40 on Tuesday. The firm has a 50-day moving average price of $107.34 and a 200 day moving average price of $108.07. Zimmer Biomet Holdings, Inc. has a twelve month low of $99.67 and a twelve month high of $133.90. The company has a market capitalization of $19.99 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 1.83 and a beta of 1.02. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the business posted $2.20 earnings per share. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ZBH shares. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Friday. Wells Fargo & Company lifted their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Stifel Nicolaus boosted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Finally, Raymond James decreased their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.